Article
The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Apr 2022
Schaefer Inga-Marie, DeMatteo Ronald P, Serrano César
Abstract excerpt
Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin and a compelling clinical and biologic model for the rational development of molecularly targeted agents. This is because the majority of GISTs are driven by gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinases. Specific GIST mutations circumscribe well-defined molecular subgroups that must be...
Topics
- Antineoplastic Agents
- Drug Resistance, Neoplasm
- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Tumors
- Humans
- Imatinib Mesylate
- Mutation
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins c-kit